← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 58.9% to $4.0M, while Net income decreased 65.5% to ($27.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $4.0MWatch
- Profitability — Net income ($27.0M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 14 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Business
CervoMed Inc.: We believe this approach enhances the alignment of our development path with neflamapimod's mechanism of action, reduces the heterogeneity of our target patient population, and provides the opportunity to demonstrate heightened clinical effect in shorter duration trials.
Where the revenue comes from
Fiscal 2025, as CervoMed Inc. reports it. History and quarterly detail are in the app.
- National Institute Of Aging Grant$4.0M
Leadership changes
From CervoMed Inc.'s own filings, the day they're filed.
- David Quigley · director · appointmenteff. 2025-10-27
- Joshua S. Boger · director · appointmenteff. 2024-02-07
- Robert J. Cobuzzi Jr · appointmenteff. 2023-11-07
Latest filings
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-14
- 8-K · Company announcement2026-07-09
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CervoMed Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.